Hester Biosciences Share Price Target 2026 Analyst Forecast Bull and Bear Case

The Hester Biosciences share price target, currently trading near its 52-week high of Rs 2,350, stands at Rs 2,425 for 2026, implying approximately 12% upside from the current market price of Rs 2,167. The stock trades at a price-to-earnings ratio of 32.24x, indicating balanced growth and value characteristics, with a market capitalisation of Rs 1,853 Cr. Investors tracking the veterinary pharma segment are closely watching Hester Biosciences as an emerging opportunity given its 52-week range of Rs 1,239 to Rs 2,350. This analysis covers the bull case, bear case, and key catalysts that will define the Hester Biosciences share price target trajectory through 2026.

Click Here – Get Free Investment Predictions

Hester Biosciences Company Overview and Key Metrics

Hester Biosciences	Details
NSE Symbol	HESTERBIO
Sector	Veterinary Pharma
CMP (Rs)	2,167
52W High (Rs)	2,350
52W Low (Rs)	1,239
Market Cap (Rs Cr)	1,853 Cr
P/E Ratio	32.24
12M Target (Rs)	2,425
Bull Case (Rs)	2,790
Bear Case (Rs)	1,950

Hester Biosciences is a veterinary pharma company listed on the National Stock Exchange (NSE: HESTERBIO). With a market capitalisation of Rs 1,853 Cr, the company occupies a defined position in the Indian veterinary pharma landscape. The stock has traded in a wide range over the past 12 months, touching a high of Rs 2,350 and a low of Rs 1,239, before arriving at its current level of Rs 2,167. Uniresearch analysts project a 12-month Hester Biosciences share price target of Rs 2,425, with a bull case of Rs 2,790 and a bear case of Rs 1,950.

Why Is the Hester Biosciences share price target Set at Rs 2,425 for 2026

FY27 Earnings Delivery and Revenue Acceleration

The Hester Biosciences share price target of Rs 2,425 is anchored in expectations of FY27 earnings delivery. At a P/E of 32.24x on trailing earnings, the stock is priced for consistent execution. Consistent revenue growth and margin improvement in coming quarters can re-rate the stock towards the Rs 2,425 target.

Domestic Formulations Growth and NLEM Coverage

India’s pharma market is expanding at 10-12% annually driven by rising health awareness and increasing prescription volumes. Companies with a strong domestic branded generic presence are well-positioned to capture this structural demand growth.

USFDA and Export Approvals Pipeline

Pharma companies that successfully navigate USFDA inspections and build a credible ANDA pipeline can see significant margin expansion through regulated market sales. Export realizations are typically three to five times domestic pricing.

RBI Rate Cut Cycle and Lower Cost of Capital

The Reserve Bank of India has shifted to an accommodative monetary policy stance, with rate cuts reducing borrowing costs across the economy. For Hester Biosciences, lower interest rates translate to reduced finance costs and potentially higher consumer demand in its end markets, creating a favourable backdrop for the Hester Biosciences share price target to materialise by year-end.

Union Budget 2026 and Policy Tailwinds

The Union Budget 2026-27 has maintained strong capex allocation of Rs 11 lakh crore for infrastructure, directly benefiting sectors including veterinary pharma. Tax rationalisation and sector-specific policy support create a constructive policy environment that supports the Hester Biosciences share price target thesis through improved demand visibility.

Hester Biosciences Share Price Target Short Term, 12 Month and Long Term

Short Term Hester Biosciences Share Price Target: 3 to 6 Months

In the near term, the Hester Biosciences share price target for the next 3 to 6 months is pegged at Rs 2,340, contingent on Q1 FY27 earnings meeting expectations and sustained buying interest in the veterinary pharma segment. Technically, the stock needs to hold the Rs 1,301-1,363 zone for this short-term target to remain valid.

12 Month Hester Biosciences Share Price Target 2026

Our 12-month Hester Biosciences share price target is Rs 2,425. This target is based on the Uniresearch fundamental estimate, which factors in FY27 revenue growth, margin normalisation, and sector re-rating potential. The Rs 2,425 level represents approximately 12% upside from the current price of Rs 2,167.

Long Term Hester Biosciences Share Price Target: FY27 to FY28

Over a 2 to 3 year horizon, the long-term Hester Biosciences share price target is estimated between Rs 2,789 and Rs 3,274, assuming continued compounding in earnings, potential capacity expansions, and improved market positioning. Investors with a multi-year holding perspective may find the current CMP of Rs 2,167 an attractive accumulation level.

Bull Case and Bear Case for Hester Biosciences Share Price Target

Bull Case: Rs 2,790

In the bull case scenario, Hester Biosciences delivers above-estimate earnings growth driven by strong demand, margin expansion, and new business wins. If these catalysts materialise simultaneously, the Hester Biosciences share price target could reach Rs 2,790, implying approximately 29% upside from the current market price.

Bear Case: Rs 1,950

The bear case of Rs 1,950 assumes earnings disappointment, sector-level de-rating, or broader market selloff driven by FII outflows. In this scenario, Hester Biosciences could re-test support levels closer to its 52-week low of Rs 1,239, representing a downside risk investors should monitor.

Scenario	Target Price (Rs)	Upside/Downside from CMP	Key Assumption
Bull Case	2,790	29%	Strong earnings growth, sector re-rating
Base Case	2,425	12%	Steady earnings, margin improvement
Bear Case	1,950	-10%	Earnings miss, macro headwinds

Key Risks to the Hester Biosciences Share Price Target 2026

Macro Headwind from Global Slowdown and US Tariff Policy

A sharper-than-expected global slowdown or escalation in US-China trade tensions could dampen demand across sectors. Hester Biosciences faces indirect risk if its customers or supply chain partners are impacted by slower global growth, as this could translate to lower order volumes or pricing pressure.

Valuation Risk and Earnings Miss Scenario

If Hester Biosciences reports quarterly earnings below analyst estimates or provides weak forward guidance, the stock could see significant de-rating. Elevated valuations in some segments leave limited margin for error, making execution risk a critical near-term concern.

Competitive Pressure in the Veterinary Pharma Segment

The veterinary pharma space in India is increasingly competitive with both domestic players and global companies vying for market share. Price competition, product commoditisation, or loss of key client contracts could pressure Hester Biosciences’s revenue trajectory.

FII Selling and Broader Market Volatility

Foreign Institutional Investor selling in Indian equities has historically led to broad-based price corrections even in fundamentally sound companies. Hester Biosciences’s share price could face near-term pressure if FII sentiment turns risk-off due to global monetary policy changes.

How to Invest in Hester Biosciences Stock

Step 1: Research and Fundamental Analysis. Before investing, thoroughly review Hester Biosciences’s quarterly results, annual report, and management commentary. Focus on revenue growth trajectory, operating margin trends, and debt levels to assess whether the Hester Biosciences share price target of Rs 2,425 is achievable.

Step 2: Use Stock Screeners for Live Data.

Check Hester Biosciences Live Data on Univest Screener

Monitor key metrics including P/E, return on equity, and promoter holding changes. These ratios can confirm or challenge the Hester Biosciences share price target thesis in real time.

Step 3: Define Your Entry Zone. The current CMP of Rs 2,167 is within the identified accumulation zone based on the 52-week low of Rs 1,239 and the Uniresearch target of Rs 2,425. Consider entering in tranches to average your cost over market fluctuations.

Step 4: Set Stop Loss and Risk Management Levels. Always define a stop-loss level before investing. A prudent stop-loss for Hester Biosciences based on the current technical setup would be in the Rs 1,907 to Rs 1,994 range. Never risk more than 2-5% of your portfolio in any single position.

Step 5: Open a Zero-Brokerage Demat Account. To invest in Hester Biosciences at zero brokerage, open your demat account with Univest, which combines SEBI-registered research with integrated trading. This allows you to act on the Hester Biosciences share price target analysis without incurring unnecessary transaction costs.

Download the Univest iOS App or Univest Android App to track Hester Biosciences live price and get daily stock recommendations.

Conclusion

The Hester Biosciences share price target for 2026 is Rs 2,425, with a bull case of Rs 2,790 and a bear case of Rs 1,950, based on Uniresearch estimates as of 29 June 2026. At a CMP of Rs 2,167 with a 52-week range of Rs 1,239 to Rs 2,350, Hester Biosciences presents a risk-reward opportunity that warrants monitoring. Investors should review Q1 FY27 results, track management commentary on guidance, and consult a SEBI-registered advisor before making investment decisions. The Hester Biosciences share price target outlined here is for educational purposes only.

FAQs on Hester Biosciences Share Price Target 2026

What is the Hester Biosciences share price target for 2026?

Ans. The Hester Biosciences share price target for 2026, as per Uniresearch estimate, is Rs 2,425. This implies approximately 12% upside from the current market price of Rs 2,167.

Is Hester Biosciences a good stock to buy right now?

Ans. Whether Hester Biosciences is a good buy depends on your investment horizon, risk appetite, and portfolio allocation. The Uniresearch Hester Biosciences share price target of Rs 2,425 implies meaningful upside, but investors must assess company fundamentals and market conditions before investing.

What is Hester Biosciences’s 52-week high and low?

Ans. Hester Biosciences’s 52-week high is Rs 2,350 and the 52-week low is Rs 1,239, as of 29 June 2026. The current price of Rs 2,167 represents a 75% gain from the 52-week low.

What is the market cap of Hester Biosciences?

Ans. The market capitalisation of Hester Biosciences is approximately Rs 1,853 Cr, as of 29 June 2026.

What are the key risks to the Hester Biosciences share price target?

Ans. Key risks to the Hester Biosciences share price target of Rs 2,425 include earnings disappointment, global macro headwinds, FII selling pressure, and competitive intensity in the veterinary pharma sector. Any of these factors could delay or reduce the target realisation.

What is the bull case target for Hester Biosciences in 2026?

Ans. In the bull case scenario, the Hester Biosciences share price target could reach Rs 2,790, implying approximately 29% upside from the current level. This assumes stronger-than-expected earnings growth and sector re-rating.

Where can I track Hester Biosciences share price live?

Ans. You can track Hester Biosciences (NSE: HESTERBIO) live price, charts, and fundamental data on the Univest app or screener. The Univest platform provides real-time price data, analyst research, and portfolio tracking in one place.

How do I invest in Hester Biosciences stock?

Ans. To invest in Hester Biosciences, open a demat account with a SEBI-registered broker like Univest, which offers zero brokerage and integrated research. Search for the ticker HESTERBIO on NSE, review fundamentals using the Univest Screener, and invest based on your financial goals and risk profile.